Basilea Pharmaceutica AG released an investor presentation outlining its anti-infectives business, including two marketed hospital brands, Cresemba and Zevtera, and an R&D pipeline focused on severe fungal and bacterial infections. The presentation highlights Cresemba in-market sales of USD 693 million for the moving annual total period ended September 2025, and notes that Zevtera was launched in the United States in July 2025 through partner Innoviva Specialty Therapeutics, with U.S. market exclusivity until April 2034. It also summarizes late-stage development programs, including phase 3 studies for fosmanogepix in invasive candidiasis and invasive mold infections, and for ceftibuten-ledaborbactam in complicated urinary tract infections, alongside disclosed non-dilutive funding arrangements with BARDA and CARB-X. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.